NCT03073473View on ClinicalTrials.gov

Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers

TerminatedOBSERVATIONAL
Enrollment

40

Participants

Timeline

Start Date

February 28, 2017

Primary Completion Date

June 13, 2018

Study Completion Date

June 13, 2018

Conditions
Pancreatic CancerMetastatic Breast CancerMetastatic Lung CancerMetastatic Colon CancerMetastatic MelanomaMetastatic Prostate Cancer
Interventions
DIAGNOSTIC_TEST

NantHealth GPS Cancer Test

Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.

Trial Locations (10)

08816

RCCA - Central Jersey Division, East Brunswick

07728

RCCA - Freehold Division, Freehold

07601

Hackensack Meridian Health System, Hackensack

07840

RCCA - Hackettstown Division, Hackettstown

07731

RCCA - Howell Division, Howell Township

07739

RCCA - Little Silver Division, Little Silver

08223

RCCA - Marmora Division, Marmora

08060

RCCA - Mount Holly Division, Mount Holly

07444

RCCA - Pompton Plains Division, Pompton Plains

07871

RCCA - Sparta Division, Sparta

Sponsors

Lead Sponsor

Cota Inc.

Collaborators (1)

NantHealth Inc.
All Listed Sponsors
collaborator

Blue Cross Blue Shield

OTHER

collaborator

NantHealth Inc.

UNKNOWN

lead

Cota Inc.

INDUSTRY

NCT03073473 - Evaluation of the NantHealth GPS Cancer Test in Patients With Advanced Cancers | Biotech Hunter | Biotech Hunter